This spring the Food and Drug Administration approved the first biosimilar drug for use in the United States, opening the regulatory door to lower-cost versions of a class of pharmaceuticals called biologics. The drug, Zarzio, helps patients receiving chemotherapy make white blood cells, preventing infections common among cancer patients. It is considered therapeutically equivalent to the existing biologic, Neupogen.
So why is this important? READ MORE